Patents Assigned to Baylor Universwity
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: RE45907
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: March 1, 2016
    Assignees: OXiGENE, Inc., Baylor Universwity
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen